Market capitalization | $1.96b |
Enterprise Value | $1.28b |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
P/B ratio (TTM) P/B ratio | 2.65 |
Revenue (TTM) Revenue | $0.00 |
EBIT (operating result TTM) EBIT | $-269.27m |
Free Cash Flow (TTM) Free Cash Flow | $-211.64m |
Cash position | $717.25m |
As a Free StocksGuide user, you can view scores for all 6,897 stocks worldwide.
9 Analysts have issued a Akero Therapeutics Inc forecast:
9 Analysts have issued a Akero Therapeutics Inc forecast:
Sep '24 |
+/-
%
|
||
Revenue | - - |
-
|
|
Gross Profit | -0.01 -0.01 |
95%
95%
|
|
EBITDA | -269 -269 |
98%
98%
|
EBIT (Operating Income) EBIT | -269 -269 |
97%
97%
|
Net Profit | -237 -237 |
98%
98%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Akero Therapeutics, Inc. operates as a biotechnology company. The firm specializes in transformational treatments for non-alcoholic steatohepatitis (NASH) and other serious metabolic diseases. The company was founded by Jonathan Young and Timothy Rolph on January 24, 2017 and is headquartered in South San Francisco, CA.
Head office | United States |
CEO | Andrew Cheng |
Employees | 56 |
Founded | 2017 |
Website | www.akerotx.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.